MEDICAGO
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 16:00:00 CEST | Press release
New Natural Language Interface Helps Clients Analyze Holdings, Performance, and Allocation in Seconds Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sect
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 15:36:00 CEST | Press release
The proposed acquisition forms part of Multiply Group’s broader strategy to build scale, enhance portfolio synergies, and drive long-term value.2PointZero brings scalable assets across energy, mining and financial services, while Ghitha Holding contributes a diversified food and agriculture platform.The transaction remains subject to shareholder and regulatory approvals, with further details to be announced upon completion of the review process. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a tr
Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 15:30:00 CEST | Press release
The Nobel Prize for Chemistry has awarded scientists for their work in metal-organic frameworks (MOFs), for their high capacity and selectivity for captured gases, including CO2. The CALF-20 MOF used in Svante’s filters for carbon capture and removal, was highlighted in the award announcement. Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/
New NIQ Report: Quality, Convenience, and Hygiene to Drive Growth in Home Appliances Market in 202615.10.2025 15:00:00 CEST | Press release
While unit sales in the Consumer Tech and Durable Goods (T&D) market remain flat at 1% growth for the first half of 2025, a 4.6% rise in dollar sales shows consumers are spending more per item.US 50% “steel equivalents” tariffs set to increase prices, impacting demand for major domestic appliances overall in the US and depressing demand for overseas brands.Chinese brands lead on innovation in the international small home appliances market, commanding increasingly premium prices.Hygiene-related appliances like vacuum cleaners, washing machines, and dishwashers saw a 6% sales growth in the first half of this year, outpacing overall T&D value growth. NielsenIQ (NYSE: NIQ) today released its Home Appliances Outlook 2026: What consumers want report, which reveals the macro forces that will shape the Home Appliances industry in 2026 and the product innovation most likely to drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom
Impartner Launches HyperscalerGTM, the First Unified Partner-to-Marketplace Automation15.10.2025 15:00:00 CEST | Press release
HyperscalerGTM is a breakthrough innovation that bridges partner management and enables partners to sell solutions directly in cloud marketplaces through an integrated deal registration workflow Impartner, the global leader in partner management and partner marketing automation, today announced the launch of HyperscalerGTM, a disruptive new solution that unifies the entire partner-to-cloud-marketplace journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015648514/en/ The launch of HyperscalerGTM represents the most significant advancement in partner automation in a decade, introducing a disruptive solution that unifies the entire partner-to-cloud-marketplace journey. For the first time ever, vendors can enable partners to register deals, collaborate with hyperscaler field teams, and transact directly in cloud marketplaces all from within a single, automated workflow. The result is a faster, simpler path from partner re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom